Novo Nordisk A/S
Novo Nordisk A/S
Your view on NVO
Overview
What the company does, where it operates, and who runs it.
About Novo Nordisk A/S
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Maziar Mike Doustdar
- Headquarters
- Novo Alle 1, Bagsvaerd, DK
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Maziar Mike Doustdar
- Headquarters
- Novo Alle 1, Bagsvaerd, DK
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Novo Nordisk A/S, and the rating behind it. NVO last traded at $39.13, 9.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Novo Nordisk A/S. Starting points for Novo Nordisk A/S: P/E 9.9, EPS $26.30, beta 0.35 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Novo Nordisk A/S. Novo Nordisk A/S paid $1.16 per share over the last year — a 3.0% yield at the current $39.13 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Novo Nordisk A/S. Trailing twelve-month EPS for Novo Nordisk A/S stands at $26.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Novo Nordisk A/S. Novo Nordisk A/S has reported as a listed company since 1981. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Novo Nordisk A/S valued side by side against its closest peers. Novo Nordisk A/S is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Novo Nordisk A/S, and how their positions are changing. At a $172.99B market value, institutional positions materially move Novo Nordisk A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Novo Nordisk A/S executives and directors. Shares of Novo Nordisk A/S have traded between $45.05 and $112.52 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Novo Nordisk A/S. Novo Nordisk A/S is a $172.99B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Novo Nordisk A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Novo Nordisk A/S. Coverage tracks Novo Nordisk A/S within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.